Promiscuous presentation of HLA class I restricted, HIV derived CTL epitopes
Project Number5R01AI067077-02
Contact PI/Project LeaderBRANDER, CHRISTIAN
Awardee OrganizationMASSACHUSETTS GENERAL HOSPITAL
Description
Abstract Text
DESCRIPTION (provided by applicant):
Promiscuous presentation of HLA class I restricted, HIV derived CTL epitopes CTL mediated cellular immunity is considered an important arm of the host defense against HIV infection and a number of HLA class I alleles have been associated with slow or fast HIV disease progression. Despite some significant advances in the field, the mechanisms by which HLA class I alleles mediate their beneficial or detrimental effects, are still unclear and may include multiple factors such as peptide binding, variability of targeted viral sequences, antigen processing and the kinetics of viral antigen expression. Recent data from murine studies have also linked T-cell receptor (TCR) repertoire diversity with relative control of viral infections. Comparing closely related MHC molecules presenting the identical epitope, these analyses revealed different TCR repertoire diversity depending on which MHC allele presented the targeted epitope and indicated that a narrow TCR repertoire was associated with CTL responses of low functional avidity and inability to control viral replication. Based on these recent reports and our own, extensive preliminary recent data, the present proposal aims to identify HIV encoded, promiscuously binding CTL epitopes that can be presented by HLA alleles differentially associated with HIV disease progression and to assess the functional avidity and TCR repertoire diversity of these CTL responses, depending on which allele the epitope is presented. Functional avidity and TCR repertoire diversity are then put in relation with the CTL's ability to efficiently recognize naturally occurring viral epitope variants and to drive viral evolution in response to immune selection pressure mediated by epitope presentation on alleles associated with wither fast or slow disease progression. Focusing on promiscuously binding CTL epitopes, the potential association between TCR repertoire diversity, functional avidity and rate of HIV disease progression can be assessed in the absence of a number of confounding effects that have limited similar analyses in the past. The emerging data will be of significant importance for HIV vaccine development and help the identification of true immune correlates of protective HIV immunity.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
HIV infectionsMHC class I antigenT cell receptorallelesantigen antibody reactionantigen presentationclinical researchcytotoxic T lymphocytehuman subjectimmune responseimmune response genespathologic processpatient oriented researchvirus antigen
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
073130411
UEI
FLJ7DQKLL226
Project Start Date
15-June-2005
Project End Date
28-February-2010
Budget Start Date
01-March-2006
Budget End Date
28-February-2007
Project Funding Information for 2006
Total Funding
$427,219
Direct Costs
$244,125
Indirect Costs
$183,094
Year
Funding IC
FY Total Cost by IC
2006
National Institute of Allergy and Infectious Diseases
$427,219
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI067077-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI067077-02
Patents
No Patents information available for 5R01AI067077-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI067077-02
Clinical Studies
No Clinical Studies information available for 5R01AI067077-02
News and More
Related News Releases
No news release information available for 5R01AI067077-02
History
No Historical information available for 5R01AI067077-02
Similar Projects
No Similar Projects information available for 5R01AI067077-02